+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global BCL-2 (B-cell lymphoma 2) Inhibitors Market 2023-2027

  • PDF Icon

    Report

  • 166 Pages
  • February 2023
  • Region: Global
  • TechNavio
  • ID: 5557965
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The BCL-2 (B-cell Lymphoma 2) inhibitors market is forecasted to grow by $1,657.08 mn during 2022-2027, accelerating at a CAGR of 12.92% during the forecast period. The report on the BCL-2 (B-cell Lymphoma 2)inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rising geriatric population, growing awareness about hematological malignancies, and high target affinity and specificity of BCL-2 inhibitors.

The BCL-2 (B-cell Lymphoma 2) inhibitors market is segmented as below:

By Product

  • Combination therapy
  • Monotherapy

By Type

  • Diffuse large B-cell lymphoma (DLBCL)
  • Follicular lymphoma
  • Chronic lymphocytic leukemia
  • Mantle cell lymphoma (MCL)

By Geography

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the increase of patient assistance programs as one of the prime reasons driving the BCL-2 (B-cell Lymphoma 2) inhibitors market growth during the next few years. Also, growing approval of combination therapy and development of novel formulations will lead to sizable demand in the market.

The report on the BCL-2 (B-cell Lymphoma 2) inhibitors market covers the following areas:

  • BCL-2 (B-cell Lymphoma 2) inhibitors market sizing
  • BCL-2 (B-cell Lymphoma 2) inhibitors market forecast
  • BCL-2 (B-cell Lymphoma 2) inhibitors market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading BCL-2 (B-cell Lymphoma 2) inhibitors market vendors that include Abcam plc, Amgen Inc., Ascentage Pharma Group International, AstraZeneca Plc, BeiGene Ltd., Bio Techne Corp., Biorbyt Ltd., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Ipsen Pharma, Merck and Co. Inc., Novartis AG, Santa Cruz Biotechnology Inc., Seagen Inc., Servier, and AbbVie Inc. Also, the BCL-2 (B-cell Lymphoma 2) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market by Geography
Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
4.1 Global BCL-2 (B-cell lymphoma 2) inhibitors market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on Global BCL-2 (B-cell lymphoma 2) inhibitors market 2017 - 2021 ($ million)
4.2 Product Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Product Segment 2017 - 2021 ($ million)
4.3 Type Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Type Segment 2017 - 2021 ($ million)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Product
6.1 Market segments
Exhibit 30: Chart on Product - Market share 2022-2027 (%)
Exhibit 31: Data Table on Product - Market share 2022-2027 (%)
6.2 Comparison by Product
Exhibit 32: Chart on Comparison by Product
Exhibit 33: Data Table on Comparison by Product
6.3 Combination therapy - Market size and forecast 2022-2027
Exhibit 34: Chart on Combination therapy - Market size and forecast 2022-2027 ($ million)
Exhibit 35: Data Table on Combination therapy - Market size and forecast 2022-2027 ($ million)
Exhibit 36: Chart on Combination therapy - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Combination therapy - Year-over-year growth 2022-2027 (%)
6.4 Monotherapy - Market size and forecast 2022-2027
Exhibit 38: Chart on Monotherapy - Market size and forecast 2022-2027 ($ million)
Exhibit 39: Data Table on Monotherapy - Market size and forecast 2022-2027 ($ million)
Exhibit 40: Chart on Monotherapy - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Monotherapy - Year-over-year growth 2022-2027 (%)
6.5 Market opportunity by Product
Exhibit 42: Market opportunity by Product ($ million)
Exhibit 43: Data Table on Market opportunity by Product ($ million)
7 Market Segmentation by Type
7.1 Market segments
Exhibit 44: Chart on Type - Market share 2022-2027 (%)
Exhibit 45: Data Table on Type - Market share 2022-2027 (%)
7.2 Comparison by Type
Exhibit 46: Chart on Comparison by Type
Exhibit 47: Data Table on Comparison by Type
7.3 Diffuse large B-cell lymphoma (DLBCL) - Market size and forecast 2022-2027
Exhibit 48: Chart on Diffuse large B-cell lymphoma (DLBCL) - Market size and forecast 2022-2027 ($ million)
Exhibit 49: Data Table on Diffuse large B-cell lymphoma (DLBCL) - Market size and forecast 2022-2027 ($ million)
Exhibit 50: Chart on Diffuse large B-cell lymphoma (DLBCL) - Year-over-year growth 2022-2027 (%)
Exhibit 51: Data Table on Diffuse large B-cell lymphoma (DLBCL) - Year-over-year growth 2022-2027 (%)
7.4 Follicular lymphoma - Market size and forecast 2022-2027
Exhibit 52: Chart on Follicular lymphoma - Market size and forecast 2022-2027 ($ million)
Exhibit 53: Data Table on Follicular lymphoma - Market size and forecast 2022-2027 ($ million)
Exhibit 54: Chart on Follicular lymphoma - Year-over-year growth 2022-2027 (%)
Exhibit 55: Data Table on Follicular lymphoma - Year-over-year growth 2022-2027 (%)
7.5 Chronic lymphocytic leukemia - Market size and forecast 2022-2027
Exhibit 56: Chart on Chronic lymphocytic leukemia - Market size and forecast 2022-2027 ($ million)
Exhibit 57: Data Table on Chronic lymphocytic leukemia - Market size and forecast 2022-2027 ($ million)
Exhibit 58: Chart on Chronic lymphocytic leukemia - Year-over-year growth 2022-2027 (%)
Exhibit 59: Data Table on Chronic lymphocytic leukemia - Year-over-year growth 2022-2027 (%)
7.6 Mantle cell lymphoma (MCL) - Market size and forecast 2022-2027
Exhibit 60: Chart on Mantle cell lymphoma (MCL) - Market size and forecast 2022-2027 ($ million)
Exhibit 61: Data Table on Mantle cell lymphoma (MCL) - Market size and forecast 2022-2027 ($ million)
Exhibit 62: Chart on Mantle cell lymphoma (MCL) - Year-over-year growth 2022-2027 (%)
Exhibit 63: Data Table on Mantle cell lymphoma (MCL) - Year-over-year growth 2022-2027 (%)
7.7 Market opportunity by Type
Exhibit 64: Market opportunity by Type ($ million)
Exhibit 65: Data Table on Market opportunity by Type ($ million)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 67: Chart on Market share by geography 2022-2027 (%)
Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 Canada - Market size and forecast 2022-2027
Exhibit 91: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 92: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 93: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibit 94: Data Table on Canada - Year-over-year growth 2022-2027 (%)
9.9 Germany - Market size and forecast 2022-2027
Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%)
9.10 UK - Market size and forecast 2022-2027
Exhibit 99: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 100: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 101: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibit 102: Data Table on UK - Year-over-year growth 2022-2027 (%)
9.11 France - Market size and forecast 2022-2027
Exhibit 103: Chart on France - Market size and forecast 2022-2027 ($ million)
Exhibit 104: Data Table on France - Market size and forecast 2022-2027 ($ million)
Exhibit 105: Chart on France - Year-over-year growth 2022-2027 (%)
Exhibit 106: Data Table on France - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity by geography
Exhibit 107: Market opportunity by geography ($ million)
Exhibit 108: Data Tables on Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 AbbVie Inc.
Exhibit 115: AbbVie Inc. - Overview
Exhibit 116: AbbVie Inc. - Product/Service
Exhibit 117: AbbVie Inc. - Key news
Exhibit 118: AbbVie Inc. - Key offerings
12.4 Abcam plc
Exhibit 119: Abcam plc - Overview
Exhibit 120: Abcam plc - Product/Service
Exhibit 121: Abcam plc - Key news
Exhibit 122: Abcam plc - Key offerings
12.5 Amgen Inc.
Exhibit 123: Amgen Inc. - Overview
Exhibit 124: Amgen Inc. - Product/Service
Exhibit 125: Amgen Inc. - Key offerings
12.6 Ascentage Pharma Group International
Exhibit 126: Ascentage Pharma Group International - Overview
Exhibit 127: Ascentage Pharma Group International - Product/Service
Exhibit 128: Ascentage Pharma Group International - Key offerings
12.7 AstraZeneca Plc
Exhibit 129: AstraZeneca Plc - Overview
Exhibit 130: AstraZeneca Plc - Product/Service
Exhibit 131: AstraZeneca Plc - Key news
Exhibit 132: AstraZeneca Plc - Key offerings
12.8 BeiGene Ltd.
Exhibit 133: BeiGene Ltd. - Overview
Exhibit 134: BeiGene Ltd. - Business segments
Exhibit 135: BeiGene Ltd. - Key offerings
Exhibit 136: BeiGene Ltd. - Segment focus
12.9 Bio Techne Corp.
Exhibit 137: Bio Techne Corp. - Overview
Exhibit 138: Bio Techne Corp. - Business segments
Exhibit 139: Bio Techne Corp. - Key news
Exhibit 140: Bio Techne Corp. - Key offerings
Exhibit 141: Bio Techne Corp. - Segment focus
12.10 Biorbyt Ltd.
Exhibit 142: Biorbyt Ltd. - Overview
Exhibit 143: Biorbyt Ltd. - Product/Service
Exhibit 144: Biorbyt Ltd. - Key offerings
12.11 Bristol Myers Squibb Co.
Exhibit 145: Bristol Myers Squibb Co. - Overview
Exhibit 146: Bristol Myers Squibb Co. - Product/Service
Exhibit 147: Bristol Myers Squibb Co. - Key news
Exhibit 148: Bristol Myers Squibb Co. - Key offerings
12.12 F. Hoffmann La Roche Ltd.
Exhibit 149: F. Hoffmann La Roche Ltd. - Overview
Exhibit 150: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 151: F. Hoffmann La Roche Ltd. - Key news
Exhibit 152: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 153: F. Hoffmann La Roche Ltd. - Segment focus
12.13 Merck and Co. Inc.
Exhibit 154: Merck and Co. Inc. - Overview
Exhibit 155: Merck and Co. Inc. - Business segments
Exhibit 156: Merck and Co. Inc. - Key news
Exhibit 157: Merck and Co. Inc. - Key offerings
Exhibit 158: Merck and Co. Inc. - Segment focus
12.14 Novartis AG
Exhibit 159: Novartis AG - Overview
Exhibit 160: Novartis AG - Business segments
Exhibit 161: Novartis AG - Key offerings
Exhibit 162: Novartis AG - Segment focus
12.15 Santa Cruz Biotechnology Inc.
Exhibit 163: Santa Cruz Biotechnology Inc. - Overview
Exhibit 164: Santa Cruz Biotechnology Inc. - Product/Service
Exhibit 165: Santa Cruz Biotechnology Inc. - Key offerings
12.16 Seagen Inc.
Exhibit 166: Seagen Inc. - Overview
Exhibit 167: Seagen Inc. - Product/Service
Exhibit 168: Seagen Inc. - Key offerings
12.17 Servier
Exhibit 169: Servier - Overview
Exhibit 170: Servier - Business segments
Exhibit 171: Servier - Key offerings
Exhibit 172: Servier - Segment focus
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 173: Inclusions checklist
Exhibit 174: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 175: Currency conversion rates for US$
13.4 Research methodology
Exhibit 176: Research methodology
Exhibit 177: Validation techniques employed for market sizing
Exhibit 178: Information sources
13.5 List of abbreviations
Exhibit 179: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market by Geography
Exhibits 5: Executive Summary - Chart on Market Segmentation by Product
Exhibits 6: Executive Summary - Chart on Market Segmentation by Type
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibits 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibits 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits 18: Historic Market Size - Data Table on Global BCL-2 (B-cell lymphoma 2) inhibitors market 2017 - 2021 ($ million)
Exhibits 19: Historic Market Size - Product Segment 2017 - 2021 ($ million)
Exhibits 20: Historic Market Size - Type Segment 2017 - 2021 ($ million)
Exhibits 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
Exhibits 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
Exhibits 23: Five forces analysis - Comparison between 2022 and 2027
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
Exhibits 26: Threat of new entrants - Impact of key factors in 2022 and 2027
Exhibits 27: Threat of substitutes - Impact of key factors in 2022 and 2027
Exhibits 28: Threat of rivalry - Impact of key factors in 2022 and 2027
Exhibits 29: Chart on Market condition - Five forces 2022 and 2027
Exhibits 30: Chart on Product - Market share 2022-2027 (%)
Exhibits 31: Data Table on Product - Market share 2022-2027 (%)
Exhibits 32: Chart on Comparison by Product
Exhibits 33: Data Table on Comparison by Product
Exhibits 34: Chart on Combination therapy - Market size and forecast 2022-2027 ($ million)
Exhibits 35: Data Table on Combination therapy - Market size and forecast 2022-2027 ($ million)
Exhibits 36: Chart on Combination therapy - Year-over-year growth 2022-2027 (%)
Exhibits 37: Data Table on Combination therapy - Year-over-year growth 2022-2027 (%)
Exhibits 38: Chart on Monotherapy - Market size and forecast 2022-2027 ($ million)
Exhibits 39: Data Table on Monotherapy - Market size and forecast 2022-2027 ($ million)
Exhibits 40: Chart on Monotherapy - Year-over-year growth 2022-2027 (%)
Exhibits 41: Data Table on Monotherapy - Year-over-year growth 2022-2027 (%)
Exhibits 42: Market opportunity by Product ($ million)
Exhibits 43: Data Table on Market opportunity by Product ($ million)
Exhibits 44: Chart on Type - Market share 2022-2027 (%)
Exhibits 45: Data Table on Type - Market share 2022-2027 (%)
Exhibits 46: Chart on Comparison by Type
Exhibits 47: Data Table on Comparison by Type
Exhibits 48: Chart on Diffuse large B-cell lymphoma (DLBCL) - Market size and forecast 2022-2027 ($ million)
Exhibits 49: Data Table on Diffuse large B-cell lymphoma (DLBCL) - Market size and forecast 2022-2027 ($ million)
Exhibits 50: Chart on Diffuse large B-cell lymphoma (DLBCL) - Year-over-year growth 2022-2027 (%)
Exhibits 51: Data Table on Diffuse large B-cell lymphoma (DLBCL) - Year-over-year growth 2022-2027 (%)
Exhibits 52: Chart on Follicular lymphoma - Market size and forecast 2022-2027 ($ million)
Exhibits 53: Data Table on Follicular lymphoma - Market size and forecast 2022-2027 ($ million)
Exhibits 54: Chart on Follicular lymphoma - Year-over-year growth 2022-2027 (%)
Exhibits 55: Data Table on Follicular lymphoma - Year-over-year growth 2022-2027 (%)
Exhibits 56: Chart on Chronic lymphocytic leukemia - Market size and forecast 2022-2027 ($ million)
Exhibits 57: Data Table on Chronic lymphocytic leukemia - Market size and forecast 2022-2027 ($ million)
Exhibits 58: Chart on Chronic lymphocytic leukemia - Year-over-year growth 2022-2027 (%)
Exhibits 59: Data Table on Chronic lymphocytic leukemia - Year-over-year growth 2022-2027 (%)
Exhibits 60: Chart on Mantle cell lymphoma (MCL) - Market size and forecast 2022-2027 ($ million)
Exhibits 61: Data Table on Mantle cell lymphoma (MCL) - Market size and forecast 2022-2027 ($ million)
Exhibits 62: Chart on Mantle cell lymphoma (MCL) - Year-over-year growth 2022-2027 (%)
Exhibits 63: Data Table on Mantle cell lymphoma (MCL) - Year-over-year growth 2022-2027 (%)
Exhibits 64: Market opportunity by Type ($ million)
Exhibits 65: Data Table on Market opportunity by Type ($ million)
Exhibits 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 67: Chart on Market share by geography 2022-2027 (%)
Exhibits 68: Data Table on Market share by geography 2022-2027 (%)
Exhibits 69: Chart on Geographic comparison
Exhibits 70: Data Table on Geographic comparison
Exhibits 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibits 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibits 73: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibits 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
Exhibits 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibits 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
Exhibits 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibits 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
Exhibits 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits 87: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibits 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibits 89: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibits 90: Data Table on US - Year-over-year growth 2022-2027 (%)
Exhibits 91: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibits 92: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibits 93: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibits 94: Data Table on Canada - Year-over-year growth 2022-2027 (%)
Exhibits 95: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits 96: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits 97: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibits 98: Data Table on Germany - Year-over-year growth 2022-2027 (%)
Exhibits 99: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibits 100: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibits 101: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibits 102: Data Table on UK - Year-over-year growth 2022-2027 (%)
Exhibits 103: Chart on France - Market size and forecast 2022-2027 ($ million)
Exhibits 104: Data Table on France - Market size and forecast 2022-2027 ($ million)
Exhibits 105: Chart on France - Year-over-year growth 2022-2027 (%)
Exhibits 106: Data Table on France - Year-over-year growth 2022-2027 (%)
Exhibits 107: Market opportunity by geography ($ million)
Exhibits 108: Data Tables on Market opportunity by geography ($ million)
Exhibits 109: Impact of drivers and challenges in 2022 and 2027
Exhibits 110: Overview on Criticality of inputs and Factors of differentiation
Exhibits 111: Overview on factors of disruption
Exhibits 112: Impact of key risks on business
Exhibits 113: Vendors covered
Exhibits 114: Matrix on vendor position and classification
Exhibits 115: AbbVie Inc. - Overview
Exhibits 116: AbbVie Inc. - Product/Service
Exhibits 117: AbbVie Inc. - Key news
Exhibits 118: AbbVie Inc. - Key offerings
Exhibits 119: Abcam plc - Overview
Exhibits 120: Abcam plc - Product/Service
Exhibits 121: Abcam plc - Key news
Exhibits 122: Abcam plc - Key offerings
Exhibits 123: Amgen Inc. - Overview
Exhibits 124: Amgen Inc. - Product/Service
Exhibits 125: Amgen Inc. - Key offerings
Exhibits 126: Ascentage Pharma Group International - Overview
Exhibits 127: Ascentage Pharma Group International - Product/Service
Exhibits 128: Ascentage Pharma Group International - Key offerings
Exhibits 129: AstraZeneca Plc - Overview
Exhibits 130: AstraZeneca Plc - Product/Service
Exhibits 131: AstraZeneca Plc - Key news
Exhibits 132: AstraZeneca Plc - Key offerings
Exhibits 133: BeiGene Ltd. - Overview
Exhibits 134: BeiGene Ltd. - Business segments
Exhibits 135: BeiGene Ltd. - Key offerings
Exhibits 136: BeiGene Ltd. - Segment focus
Exhibits 137: Bio Techne Corp. - Overview
Exhibits 138: Bio Techne Corp. - Business segments
Exhibits 139: Bio Techne Corp. - Key news
Exhibits 140: Bio Techne Corp. - Key offerings
Exhibits 141: Bio Techne Corp. - Segment focus
Exhibits 142: Biorbyt Ltd. - Overview
Exhibits 143: Biorbyt Ltd. - Product/Service
Exhibits 144: Biorbyt Ltd. - Key offerings
Exhibits 145: Bristol Myers Squibb Co. - Overview
Exhibits 146: Bristol Myers Squibb Co. - Product/Service
Exhibits 147: Bristol Myers Squibb Co. - Key news
Exhibits 148: Bristol Myers Squibb Co. - Key offerings
Exhibits 149: F. Hoffmann La Roche Ltd. - Overview
Exhibits 150: F. Hoffmann La Roche Ltd. - Business segments
Exhibits 151: F. Hoffmann La Roche Ltd. - Key news
Exhibits 152: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits 153: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits 154: Merck and Co. Inc. - Overview
Exhibits 155: Merck and Co. Inc. - Business segments
Exhibits 156: Merck and Co. Inc. - Key news
Exhibits 157: Merck and Co. Inc. - Key offerings
Exhibits 158: Merck and Co. Inc. - Segment focus
Exhibits 159: Novartis AG - Overview
Exhibits 160: Novartis AG - Business segments
Exhibits 161: Novartis AG - Key offerings
Exhibits 162: Novartis AG - Segment focus
Exhibits 163: Santa Cruz Biotechnology Inc. - Overview
Exhibits 164: Santa Cruz Biotechnology Inc. - Product/Service
Exhibits 165: Santa Cruz Biotechnology Inc. - Key offerings
Exhibits 166: Seagen Inc. - Overview
Exhibits 167: Seagen Inc. - Product/Service
Exhibits 168: Seagen Inc. - Key offerings
Exhibits 169: Servier - Overview
Exhibits 170: Servier - Business segments
Exhibits 171: Servier - Key offerings
Exhibits 172: Servier - Segment focus
Exhibits 173: Inclusions checklist
Exhibits 174: Exclusions checklist
Exhibits 175: Currency conversion rates for US$
Exhibits 176: Research methodology
Exhibits 177: Validation techniques employed for market sizing
Exhibits 178: Information sources
Exhibits 179: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global BCL-2 (B-cell lymphoma 2) inhibitors market: Abcam plc, Amgen Inc., Ascentage Pharma Group International, AstraZeneca Plc, BeiGene Ltd., Bio Techne Corp., Biorbyt Ltd., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Ipsen Pharma, Merck and Co. Inc., Novartis AG, Santa Cruz Biotechnology Inc., Seagen Inc., Servier, and AbbVie Inc.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increase of patient assistance programs.'

According to the report, one of the major drivers for this market is the rising geriatric population.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abcam plc
  • Amgen Inc.
  • Ascentage Pharma Group International
  • AstraZeneca Plc
  • BeiGene Ltd.
  • Bio Techne Corp.
  • Biorbyt Ltd.
  • Bristol Myers Squibb Co.
  • F. Hoffmann La Roche Ltd.
  • Ipsen Pharma
  • Merck and Co. Inc.
  • Novartis AG
  • Santa Cruz Biotechnology Inc.
  • Seagen Inc.
  • Servier
  • AbbVie Inc.